Senior Vice President, Late-Stage Clinical Development

Revolution Medicines•Redwood City, CA

4d•$419,000 - $523,000

About The Position

The Senior Vice President, Late-Stage Clinical Development is a senior executive leadership role reporting to the Chief Medical Officer and leading the late-stage clinical development organization. As Revolution Medicines moves from one approved medicine to a multi-asset, multi-indication late-stage portfolio, this leader will shape the overall clinical development strategy and, in partnership with the Chief Medical Officer, translate it into an integrated company development plan. The role owns registrational and Phase 3 programs across all assets. The executive works through Global Development Team Leads to shape trials, interpret emerging data, and develop strategies to change standards of care in difficult-to-treat tumors. They are accountable for building and developing the late-stage organization, including hiring and developing team leads and aligning clinical scientists with the programs they support. The role partners with the Chief Medical Officer and Chief Development Officer on portfolio strategy, collaborates with regulatory, research, biometrics, and commercial leaders, and represents the company with clinical collaboration partners. It may include co-chairing a joint steering or joint development committee and leading a disease-area franchise. The scope is expected to grow as the organization and portfolio expand.

Requirements

MD or MD/PhD and training as a medical oncologist.
Substantial late-stage oncology development experience, including accountability for registrational and Phase 3 programs and global regulatory filings.
Track record leading development teams across multiple concurrent assets.
Demonstrated ability to build and structure a clinical development organization, including hiring program leaders and building teams beneath them.
Strong scientific judgment and credibility to guide experienced development leaders.
Ability to operate effectively in a fast-moving, evolving organization and build alignment across senior stakeholders.
Motivation to make a pipeline impact and change the standard of care in difficult tumors.

Nice To Haves

Depth in pancreatic, colorectal, or lung cancer.

Responsibilities

Drive late-stage clinical development strategy across the RAS(ON) portfolio and map it into an integrated company development plan with the Chief Medical Officer.
Own registrational and Phase 3 trials across programs and assets, from design through readout and submission support.
Shape indication sequencing, study design, endpoint selection, and combination strategy with research, regulatory, biometrics, and commercial leadership.
Lead, develop, and grow the Global Development Team Leads, and guide the development and defense of their clinical development plans.
Build a late-stage organization with clear program ownership, structured so team leads hire and lead their own teams.
Partner with regulatory affairs on global filings, health authority interactions, and lifecycle planning.
Partner with the Chief Medical Officer and Chief Development Officer on portfolio strategy and prioritization.
Represent the company with clinical collaboration partners, potentially co-chairing a joint steering or joint development committee.
Engage investigators, key opinion leaders, and the broader oncology community on the company's late-stage programs and data.